Icotrokinra
Approved for plaque psoriasis in the US and EU in 2026.
A peptide taken as a once-daily tablet. It blocks the receptor, the pathway that some injected psoriasis biologics target. An made by Johnson & Johnson (with Protagonist), also called Icotyde and JNJ-2113.
What the evidence shows
Side effects and risks
Who should avoid it: Ask the prescriber about infections and vaccines, as with other drugs that act on IL-23.
How it works
- Where it acts
- It blocks IL-23 receptors on immune cells.
- What it changes
- It turns down the immune signalling that drives psoriasis plaques.
- What people notice
- Clearer skin over weeks to months in trials, with side effects close to placebo.
How it is taken
One 200 mg tablet a day on waking, with water, at least 30 minutes before food. For adults, and children from age 12 who weigh at least 40 kg.
Getting it in the United States
The legal route for Icotrokinra
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription from a dermatologist
FDA approved in 2026-03 for moderate to severe plaque psoriasis in adults and in adolescents 12 and over weighing at least 40 kg who qualify for systemic therapy or phototherapy. Sources checked give no price or coverage details.
Source: Drugs.com approval history, 2026
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Said the once-daily pill pairs skin clearance with a favourable safety profile. Called it a possible game-changer as guidance shifts patients from repeated topical treatment to systemic therapy sooner.
Source: Healio, 2026-03
Linda Stein GoldSourceRecommends
Cautionary expert view
No sourced expert view in this category yet. See the full list for other perspectives.
See all views 5
Said the once-daily pill pairs skin clearance with a favourable safety profile. Called it a possible game-changer as guidance shifts patients from repeated topical treatment to systemic therapy sooner.
Source: Healio, 2026-03
Linda Stein GoldSourceRecommends
Said the pill could anchor the company's next IL-23 strategy if phase 3 confirms the colitis data. Forecast about 3.2 billion dollars in 2031 sales, with some overlap with the company's injectable.
Source: Clinical Trials Arena, 2025-10
Vasilis RoumpelakisSourceMixed view
Described the FDA approval as a pivotal moment for people living with plaque psoriasis.
Source: Healio, 2026-03
Money: Executive at the company that sells the drug
Photo source: jnj.com
Said most advanced psoriasis treatments are injected and many people, children especially, dislike needles. Presented the drug as targeted treatment in a daily pill.
Mark SmytheWebsiteRecommends
Money: Founded the co-discovering company and held executive roles there until 2022
Photo source: infensabioscience.com
Called it a life-changing drug for people with psoriasis and credited Australian peptide science at the Queensland institute where the company began.
Greg BourneSourceRecommends
Money: Employee of the co-discovering company
More contextCase reports, watch and read, emerging uses and chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Benefit reportedtrial result in rare group - 2026
Adolescents aged 12 and over in the main phase 3 trial did better than the overall group. At week 24, about 86 percent had clear or almost clear skin and about 89 percent reached a 90 percent improvement score.
Source: Contemporary Pediatrics, 2026-03
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
FDA approves Johnson & Johnson's oral pill for psoriasis, company says
Bob D'Angelo, Cox Media Group
News report that US regulators cleared J&J's Icotyde pill for adults and patients 12 and up with plaque psoriasis, and how it competes with rivals.
Short, plain news account of the approval.
FDA Approves Icotrokinra (Icotyde): First Oral IL-23 Receptor Antagonist for Moderate-to-Severe Plaque Psoriasis
Patrick Campbell
Summarizes the approval of once-daily oral icotrokinra for moderate-to-severe plaque psoriasis in ages 12 and up, based on phase 3 ICONIC trials.
Gives the trial basis for the approval.
Key Points on Icotrokinra Following FDA Approval for Psoriasis, With Linda Stein Gold, MD
Dr Linda Stein Gold, dermatologist
A dermatologist discusses what the approval of icotrokinra means for psoriasis care and the main points clinicians should know.
Specialist perspective right after approval.
Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD
Dr Linda Stein Gold, dermatologist
A dermatologist summarizes the clinical data on oral icotrokinra for psoriasis and the practical takeaways for treating patients.
Trial data explained by a practising dermatologist.
When options run out
Uses people turn to when standard treatment has failed.
Ulcerative colitis, oral IL-23 blockade
- Who
- Adults with moderate to severe colitis who want a pill. Current IL-23 drugs for colitis are injected or infused.
- Evidence
- Phase 2b trial: about 64 percent responded at 12 weeks against 27 percent on placebo. Remission about 30 percent against 11 percent. Phase 3 not finished.
- Route
- Phase 3 ICONIC-UC trial, NCT07196748, adults and adolescents, due 2028
Source: Clinical Trials Arena, 2025-10
Scalp and genital psoriasis
- Who
- People with psoriasis in hard-to-treat, high-impact sites where creams often fail.
- Evidence
- The company reported results for scalp and genital psoriasis in 2025. Not a separate approved indication.
Source: Drugs.com approval history, 2026
Crohn's disease and psoriatic arthritis
- Who
- Patients with other IL-23 driven diseases who now rely on injected biologics.
- Evidence
- Studies are under way. No results or filings are reported yet for these uses.
- Route
- Company clinical trials
Source: Drugs.com approval history, 2026
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
What is icotrokinra approved for?
Moderate-to-severe plaque psoriasis, sold as Icotyde. FDA approved it in March 2026 and the EU authorized it in September 2026, for adults and children from age 12 who weigh at least 40 kg.
How well does icotrokinra work for psoriasis?
In the two head-to-head ICONIC-ADVANCE trials, about 70% of people reached clear or almost clear skin at 16 weeks.
Is icotrokinra a pill or an injection?
A pill. It is a peptide taken as one tablet a day on waking, with water, at least 30 minutes before food.
What are the side effects of icotrokinra?
Side-effect rates in the trials were within about one percentage point of placebo. It is new, so rare or long-term effects will show only with wider use; ask the prescriber about infections and vaccines.
Does icotrokinra work for ulcerative colitis?
In a phase 2b trial, about 64% responded against 27% on placebo. Phase 3 trials are running in ulcerative colitis, psoriatic arthritis and Crohn's disease.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem